Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506
Latest Information Update: 05 Apr 2023
At a glance
- Drugs YYC 506 (Primary)
- Indications Dyslipidaemias
- Focus Pharmacokinetics
- Sponsors Yooyoung Pharmaceutical
- 10 May 2021 New trial record